Ventyx Biosciences Inc

Ventyx Biosciences — Investor Presentation (November 2022)

44 slides from Ventyx Biosciences's investor presentation, Nov 30, 2022

  1. Slide 1: Corporate Presentation December 2022

    Exhibit 99.1 Corporate Presentation December 2022 1

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements Ventyx Biosciences, Inc. (“we,” “us,” “our,” “Ventyx,” or the “Company”) cautions you that statements contained in this presentation regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company’s current beliefs

  3. Slide 3: Our Mission: To Become a Leading Immunology Company

    Our Mission: To Become a Leading Immunology Company Underpinned by Strong Drug Discovery and Development Capabilities With Three, Differentiated, Clinical-stage Candidates and a deep pipeline of preclinical programs that target immune-mediated and inflammatory disease indications Our Internally-disc

  4. Slide 4: Our Leadership Team

    Our Leadership Team Management Raju Mohan, PhD Martin Auster, MD Chris Krueger, JD John Nuss, PhD William Sandborn, MD CHIEF EXECUTIVE OFFICER, CHIEF FINANCIAL OFFICER CHIEF BUSINESS OFFICER CHIEF SCIENTIFIC OFFICER PRESIDENT, CHIEF MEDICAL OFFICER FOUNDER Board Of Directors Sheila Gujrathi, MD Jiga

  5. Slide 5: Broad Pipeline of Candidates With Multiple Near-Term Catalysts

    Broad Pipeline of Candidates With Multiple Near-Term Catalysts Addressing Established Inflammatory and Immunology Markets with a Wholly Owned Product Portfolio Target Program Preclinical Phase 1 Phase 2 Phase 3 Next Anticipated Milestones Initiate Phase 2 trials Q4 2022 TYK2 VTX958 Psoriasis, psoria

  6. Slide 6: Pipeline Targeting Large Well-Established Markets

    Pipeline Targeting Large Well-Established Markets Indication* Patients In The U.S. Global Drug Revenue* (2020) Target Population Psoriasis 25-30% ~8M ~$20B Dermatology Moderate-to-severe Crohn’s disease 30-40% ~700K ~$13B IBD Moderate-to-severe Ulcerative colitis 30-40% ~1M ~$7B IBD Moderate-to-seve

  7. Slide 7: Orally Bioavailable selective allosteric inhibitor of TYK2

    ORALLY BIOAVAILABLE selective allosteric inhibitor of TYK2

  8. Slide 8: VTX958: Orally Bioavailable, Selective Allosteric Inhibitor of TYK2

    VTX958: Orally Bioavailable, Selective Allosteric Inhibitor of TYK2 Clinically Validated Potential Best-in-Class Large Addressable Target Drug Markets • Established clinical efficacy in IBD, • Selective allosteric TYK2 inhibitor • Multiple autoimmune disorders in psoriasis and psoriatic arthritis wi

  9. Slide 9: VTX958 Binds Selectively to the TYK2 Allosteric (JH2) Domain

    VTX958 Binds Selectively to the TYK2 Allosteric (JH2) Domain Key Players in JAK/TYK2 Inhibited Active Inactive IL-12, IL-23, IFNα Family Signaling Features of VTX958 JH2 Allosteric Domain JH2 Allosteric Inhibition Much less conserved amongst the JAK family Selectivity for TYK2 JH2 vs. with structura

  10. Slide 10: VTX958 is Highly Selective for TYK2 JH2 Domain vs. Deucravacitinib

    VTX958 is Highly Selective for TYK2 JH2 Domain vs. Deucravacitinib Inhibits TYK2 Pathways (IL-12, IL-23, IFNα) while Avoiding the JAK1/2/3 Pathways TYK2 JH2 domain Structural Rationale for VTX958 Selectivity: • Productive interaction for both VTX958 and deucravacitinib with valine residue in TYK2 JH

  11. Slide 11: VTX958 Selectively Inhibits IL-12, IL-23 and IFNα Signaling

    VTX958 Selectively Inhibits IL-12, IL-23 and IFNα Signaling VTX958 Has No Measurable Inhibition VTX958 Potently Inhibits TYK2 Pathways of JAK1-Mediated Pathways Selective and potent inhibition of IL-12/23 and IFNα Lack of inhibition of IL-6, IL-10, IL-22 and other protective axis allows targeting pa

  12. Slide 12: Summary of VTX958 Phase 1 Results

    Summary of VTX958 Phase 1 Results Safety, Exposure and Target Coverage VTX958 well tolerated across all SAD and MAD cohorts VTX958 exhibits class-leading • Achieved TYK2 IC coverage for up to 24 hours with no dose-limiting toxicities 90 TYK2 IC coverage* 90 Robust, dose-dependent • Supports hypothes

  13. Slide 13: VTX958 Phase 1 MAD Results: Exposure and Target Coverage

    VTX958 Phase 1 Day 10 (Steady State) MAD Results Exposure and Target Coverage Across All Cohorts Target Coverage* (hours) KEY TAKEAWAYS IFNα IL-12 IL-23 MAD Dose • Safely achieved class-leading IC IC IC IC IC IC 90 50 90 50 90 50 TYK2 IC coverage 90 50 mg BID 0 505 07 • IC coverage up to 24 hours 90

  14. Slide 14: VTX958 Phase 1 MAD Pre-IFNα Challenge Safety Assessment

    VTX958 Phase 1 MAD Pre-IFNα Challenge Safety Assessment* VTX958 Placebo 50mg BID 250mg QD 175mg BID 500mg QD 350mg BID All cohorts TEAEs (n=10) (n=6) (n=6) (n=6) (n=6) (n=6) (n=30) Headache 1 (10.0%) - 2 (33.3%) 2 (33.3%) 1 (16.7%) 1 (16.7%) 6 (20.0%) @ Faeces soft 1 (10.0%) 1 (16.7%) 2 (16.7%) 1 (1

  15. Slide 15: VTX958 Phase 1 MAD Results: Selected Laboratory Data

    VTX958 Phase 1 MAD Results: Selected Laboratory Data No significant effects on hematological parameters, lipids, CPK laboratory values Hemoglobin Neutrophils CPK 250 200 150 100 50 0 DAY 1 DAY 2 DAY 5 DAY 7 DAY 10 Platelets Lymphocytes Cholesterol 15 Hemoglobin (g/L) Lymphocytes (10^9/L) (Mean ± SD)

  16. Slide 16: VTX958 Phase 1 MAD Results: Dose-Dependent Pharmacodynamic Effects

    VTX958 Phase 1 MAD Results Robust Dose-Dependent Pharmacodynamic Effects Complete suppression of IL-12 signaling Robust inhibition of TYK2-responsive genes CXCL10, ISG20, IFI27 • Dose-dependent inhibition of IFNγ at all time-points • Genes are direct downstream targets of IFNα and display diverse in

  17. Slide 17: Published TYK2 Target Coverage Data

    Published TYK2 Target Coverage Data Opportunity for VTX958 to Differentiate with Improved Therapeutic Window Deucravacitinib (BMS) 6 mg & 12 mg QD Target Coverage Deucravacitinib (BMS) 6 mg & 12 mg QD Target Coverage First-generation allosteric TYK2 inhibitor exposures are limited by toxicities 150

  18. Slide 18: Deucravacitinib - Skin AEs and Target Coverage

    Deucravacitinib - Skin AEs and Target Coverage Deucravacitinib VTX958 Phase 1 Data Establish Study Skin AE 3 mg BID 6 mg QD 6 mg BID 12 mg QD 12 mg BID Total Differentiation vs. Deucravacitinib P1 MAD HV Any skin related AEs 33% 56% 78% 42% • Deucravacitinib elicits dose- P2 PsO Acne 2% 4% 9% depend

  19. Slide 19: Acne, Folliculitis and Rash are not On-Target Effects

    Acne, Folliculitis and Rash are not On-Target Effects of IFNα or IL12/23 Inhibition Drug Mechanism of Acne Folliculitis Rash inhibition Anifrolumab (Saphnelo) IFNα < 2% < 2% < 2% Ustekinumab (Stelara) IL12/23 < 1% < 1% < 1% Guselkumab (Tremfya) Anti-IL23 < 1% < 1% < 1% Risankizumab (Skyrizi) Anti-IL

  20. Slide 20: VTX958 vs. Competitor Allosteric TYK2 Inhibitors: Phase 1 Comparison

    VTX958 vs. Competitor Allosteric TYK2 Inhibitors Comparison of Phase 1 Safety and Exposures Data* in Healthy Volunteers VTX958 NDI-034858 Deucravacitinib Phase 1 MAD Phase 1 MAD Phase 1 MAD 100 mg – 700 mg TDD 20 mg – 35 mg QD 2 mg – 24 mg TDD 50 mg – 100 mg QD • Acneiform dermatitis (67%, 17%) • Sk

  21. Slide 21: VTX958 vs. Competitor Allosteric TYK2 Inhibitors

    VTX958 vs. Competitor Allosteric TYK2 Inhibitors Demonstrates Potential Best-in-Class Therapeutic Window Differentiating Parameter VTX958 Deucravacitinib NDI-034858 Relevant Dose / Exposure Comparisons 175 mg BID 6 mg QD 30 mg QD Target Coverage:* TYK2 IC 24 hours 9 hours 24 hours 50 TYK2 IC 16 hour

  22. Slide 22: VTX958 Profile Expected to Drive Clinical Differentiation

    VTX958 Profile Expected to Drive Clinical Differentiation Best-in-Disease Oral Potential in the ~$20B WW Annual Psoriasis Market Psoriasis Competitive Landscape 100% 86-91% 76-90% VTX958 Target Profile 80% Greater TYK2 suppression may produce improved efficacy compared to other 54-59% 60% oral agent

  23. Slide 23: Unlocking the Opportunity in IBD

    Unlocking the Opportunity in IBD Higher Doses Required for Efficacy in Crohn’s Disease Greater TYK2 pathway inhibition Agent PsO Dose (Induction) Crohn’s Dose (Induction) may be needed for IBD efficacy • Biologics data suggest substantially 150 mg Wks 0, 4 600 mg Wks 0, 4, 8 higher exposures are req

  24. Slide 24: VTX958: Broad Development Opportunities and Commercial Potential

    VTX958: Broad Development Opportunities and Commercial Potential • Phase 2 trials will explore a broad dose range, enabling optimal Phase 3 dose selection based on safety and maximizing target coverage – We plan to initiate three Phase 2 trials in Q4 2022 (PsO, Crohn’s and PsA) with additional Phase

  25. Slide 25: VTX958 Development Landscape

    VTX958 Development Landscape Robust Market Opportunity for a Potential Best-in-Class TYK2 Inhibitor Biologics Oral Agents INDICATION ANTI-IL-23 ANTI-IL-17 APREMILAST DEUCRAVACITINIB VTX958* VTX958 • Excellent safety profile Psoriasis +++ +++ + ++ +++ • Class-leading TYK2 coverage Psoriatic arthritis

  26. Slide 26: Robust Market Opportunity for VTX958

    Robust Market Opportunity for VTX958 • Best-in-class profile of VTX958 may enable clinical differentiation across multiple indications – VTX958 has potential to offer a differentiated clinical profile in PsO, PsA and SLE by dosing to levels that achieve greater TYK2 inhibition relative to competitor

  27. Slide 27: Peripherally Restricted S1P1R Modulator

    PERIPHERALLY RESTRICTED S1P1R MODULATOR with potential for treatment of ulcerative colitis

  28. Slide 28: VTX002 Program Summary

    VTX002 Program Summary Phase 2 S1P1R Modulator for Ulcerative Colitis Potentially Differentiated Clinically Validated Target Large Addressable Markets S1P1R Modulator • Selective S1P1R modulator • S1P1R modulators approved for • Ulcerative colitis is lead indication MS and UC with clinical trials to

  29. Slide 29: VTX002 Differentiates on Multiple Key Parameters vs. Competitors

    VTX002 Differentiates on Multiple Key Parameters vs. Competitors Potential Potential for Dif for Differentiated ferentiated Safety Safety Profile Profile No Drug-Drug No Drug-Drug Interactions Interactions Clinical Clinical P Profile rofile iin UC Patients n UC Patients Sustained lymphocyte reductio

  30. Slide 30: VTX002 Differentiates on Multiple Key Parameters vs. Competitors

    VTX002 Differentiates on Multiple Key Parameters vs. Competitors Differentiating Parameter Ozanimod Etrasimod VTX002 Receptor Selectivity S1P 1,5 S1P 1,4,5 S1P 1,5 CYP450 Interactions Yes No No Liver Enzyme Elevations Yes No No Active Metabolites Yes No No Half-life 19 h, Met 10-13 d 33 h ~20 h Fast

  31. Slide 31: Phase 1 MAD Results: Dose-Dependent Exposure and Lymphocyte Reduction

    Phase 1 MAD Results: Dose-Dependent Exposure and Lymphocyte Reduction Absolute Lymphocyte Count (ALC) Reductions of 40-50% Correlated with Clinical Efficacy Observed in UC* Pharmacokinetics Pharmacodynamics ****p< 0.0001 **** **** **** **** Placebo 2 mg 10 mg 20 mg 35 mg 45 mg • T of ~20 hours • Dem

  32. Slide 32: Phase 2 Induction Trial in Moderate-to-Severe Ulcerative Colitis

    Phase 2 Induction Trial in Moderate-to-Severe Ulcerative Colitis BASELINE WEEK 13* WEEK 52 13-Week Treatment Period 39-Week LTE Treatment Period Screening Period * includes 7-day titration R 12-Week Treatment Period VTX002, VTX002, 60 60 mg mg VTX002, VTX002, 60 60 mg mg Trial Design VTX002, VTX002,

  33. Slide 33: Underpenetrated Market for Biologic Refractory Patients

    Underpenetrated Market for Biologic Refractory Patients Addressable UC Patient Population in US ~1M UC PATIENTS • Existing agents leave room for new treatments 300K+ MODERATE-TO-SEVERE UC PATIENTS • Novel oral agents may expand penetrance of treated moderate- to-severe UC population beyond VTX002 TA

  34. Slide 34: Selective NLRP3 Inflammasome Inhibitors

    SELECTIVE NLRP3 INFLAMMASOME INHIBITORS for systemic and CNS indications

  35. Slide 35: Rationale for Targeting the NLRP3 Inflammasome

    Rationale for Targeting the NLRP3 Inflammasome NLRP3 Inflammasome Inhibitors Target IL-1β, a Key Driver of Inflammatory Disease Clinical Validation of In vivo Evidence Genetic Evidence Downstream Target • The NLRP3 inflammasome can • Gain-of-function mutations in the • IL-1β signaling, downstream of

  36. Slide 36: NLRP3 Inhibitor Program Summary

    NLRP3 Inhibitor Program Summary Peripheral NLRP3 Inhibitor: VTX2735 CNS NLRP3 Inhibitor: VTX3232 • Selective NLRP3 inhibitor • Selective compounds generated with high CNS bioavailability • Well tolerated in GLP safety and tox assessment • Novel and proprietary lead series • Phase 1 completed with at

  37. Slide 37: VTX2735 Is a Selective & Orally Bioavailable NLRP3 Inhibitor

    VTX2735 Is a Selective & Orally Bioavailable NLRP3 Inhibitor Mouse Pharmacodynamic Assay In Vitro Potency & Selectivity Non-Human Primate PK IV Clearance: 1.6 mL/min/kg; Oral Bioavailability: 80% IL-1β IC (nM) 50 human 2 monocytes On Target human 75 whole blood AIM2 >10000 Off NLRC4 >10000 Target NF

  38. Slide 38: Summary of VTX2735 Phase 1 Results

    Summary of VTX2735 Phase 1 Results Excellent Safety and Pharmacodynamic Activity • All AEs considered mild Concentration-Dependent Suppression of Safety • No LFT abnormalities IL-1β Ex Vivo üü • No dose-related increase in frequency of AEs observed • Dose-proportionate increases in exposure PK (C an

  39. Slide 39: VTX2735 Has Broad Activity Against Multiple NLRP3 Mutations

    VTX2735 Has Broad Activity Against Multiple NLRP3 Mutations Potential for Differentiation in CAPS Setting What is CAPS? IC in Blood Monocyte Assay (nM) 50 An ultra-orphan auto-inflammatory disease caused by various mutations in NLRP3 and characterized by Most 75% Severe inappropriate release of IL-1

  40. Slide 40: CNS-Penetrant NLRP3 Inhibitor VTX3232

    CNS-Penetrant NLRP3 Inhibitor VTX3232 In Vitro Potency & Selectivity Rat PK (PO, 5mg/kg) Dog PK (PO, 5mg/kg) T½ = 4.4 h; Oral Bioavailability = 75% T½ = 8 h; Oral Bioavailability = 100% IL-1β IC (nM) 50 1000 NLRP3 huWB 13 1000 Brain Conc. 100 AIM2 >10000 100 CSF Conc. > 10x ~20 x WB IC 50 WB IC 50 1

  41. Slide 41: NLRP3 Program Clinical Development Plan

    NLRP3 Program Clinical Development Plan VTX2735 Peripherally-restricted üüüüüü IND-enabling Studies IND Approved Phase 1 Initiate Phase 2 Healthy volunteers CAPS Further indications TBD Complete September 2021 Complete Q1 2023 VTX3232 IND-Enabling Studies CNS-penetrant Inhibitor Potential indication

  42. Slide 42: Our Comprehensive NLRP3 Portfolio Targets Major Inflammatory Diseases

    Our Comprehensive NLRP3 Portfolio Targets a Broad Range of Major Inflammatory Diseases NLRP3 Systemic Diseases Neuroinflammatory Diseases Peripheral NLRP3 inhibitors are designed CNS-directed NLRP3 inhibitors are designed to treat cardiovascular, dermatologic, rheumatic to treat a range of neuro-deg

  43. Slide 43: Investment Highlights

    Investment Highlights EFFICIENT & PRODUCTIVE IMMUNOLOGY PLATFORM • Internal R&D engine designed to generate candidates to address autoimmune and inflammatory diseases with high unmet need • 100% commercial rights to entire portfolio; long patent life for all product candidates POTENTIALLY DIFFERENTI

  44. Slide 44: Contact Us for Additional Information

    CONTACT US FOR ADDITIONAL INFORMATION: ir@ventyxbio.com VENTYX BIOSCIENCES, INC. 662 ENCINITAS BOULEVARD, SUITE 250 ENCINITAS, CA 92024 44

Ventyx Biosciences — Investor Presentation (November 2022) on 6ix